Viridian drug meets trial goal, falls short expectations

Viridian Therapeutics announced that its experimental drug for active thyroid eye disease has successfully met the primary endpoint in a late-stage clinical trial. While this outcome represents a significant step forward in drug development, the results reportedly fell short of broader expectations. Further analysis will be required to understand the full implications of the trial data and its potential impact on the drug's path to market approval. The company will likely provide more detailed information following a comprehensive review of the findings.